Retirewell have been the capital raisers for CBio from 2001 up...

Retirewell have been the capital raisers for CBio from 2001 up until the float using their client base.They have an extensive knowledge of Cbio and what they are saying is completly correct.The first small human trials (about 21 patients)were intravenous throught the veins and dosings from memory were between 10--25mgs.A few of these patients achieved ACR 70--which is remission.The past trial was subcutaneous delivery-through the skin requiring higher doses.So the top dose for the first trial of 25MG was the starting point to 75mg end point-which then gives an idea where efficacy begins for the following dosing trials which I believe will be done by the Phama.As an Angel investor myself(the first 20 share holders who provided seed capital to start the company)I have complete faith in the technology and apart from the hiccup we are going through at the moment I believe those that do hold will be very well rewarded.